TORNTPHARM - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.8
| Stock Code | TORNTPHARM | Market Cap | 1,43,681 Cr. | Current Price | 4,252 ₹ | High / Low | 4,483 ₹ |
| Stock P/E | 64.3 | Book Value | 250 ₹ | Dividend Yield | 0.75 % | ROCE | 27.8 % |
| ROE | 26.2 % | Face Value | 5.00 ₹ | DMA 50 | 4,166 ₹ | DMA 200 | 3,875 ₹ |
| Chg in FII Hold | 0.05 % | Chg in DII Hold | -0.09 % | PAT Qtr | 584 Cr. | PAT Prev Qtr | 606 Cr. |
| RSI | 55.7 | MACD | 2.61 | Volume | 2,98,852 | Avg Vol 1Wk | 2,89,456 |
| Low price | 3,101 ₹ | High price | 4,483 ₹ | PEG Ratio | 2.64 | Debt to equity | 0.25 |
| 52w Index | 83.3 % | Qtr Profit Var | 20.4 % | EPS | 65.0 ₹ | Industry PE | 30.2 |
📊 TORNTPHARM demonstrates strong fundamentals with ROE (26.2%) and ROCE (27.8%), reflecting efficient capital use. EPS (65.0 ₹) is healthy, and quarterly PAT remains stable (584 Cr. vs 606 Cr.). Debt-to-equity (0.25) is moderate, ensuring financial stability. However, the stock trades at a high P/E (64.3) compared to industry PE (30.2), suggesting stretched valuations. PEG ratio (2.64) indicates moderate overvaluation relative to growth. Current price (4,252 ₹) is near its 52-week high (4,483 ₹), limiting immediate upside. Dividend yield (0.75%) provides modest income support.
💡 Ideal Entry Price Zone: 3,900 ₹ – 4,100 ₹, closer to DMA support levels, for long-term investors.
📈 Exit / Holding Strategy
If already holding, consider a long-term horizon (3–5 years) given strong ROE, ROCE, and stable earnings. Partial profit booking can be considered near 4,450–4,500 ₹ (recent highs). Dividend yield is modest, so focus remains on capital appreciation. Monitor quarterly PAT trends and valuation metrics closely.
✅ Positive
- Strong ROE (26.2%) and ROCE (27.8%).
- EPS (65.0 ₹) reflects profitability.
- Moderate debt-to-equity (0.25) ensures financial stability.
- FII holdings increased slightly (+0.05%).
⚠️ Limitation
- High P/E (64.3) compared to industry PE (30.2).
- PEG ratio (2.64) indicates moderate overvaluation.
- Dividend yield (0.75%) is modest.
📉 Company Negative News
- Quarterly PAT declined slightly (606 Cr. to 584 Cr.).
- DII holdings decreased (-0.09%), showing reduced domestic institutional confidence.
📈 Company Positive News
- Strong efficiency metrics with high ROE and ROCE.
- FII holdings increased slightly, reflecting foreign investor interest.
🏭 Industry
- Industry PE (30.2) is much lower, highlighting TORNTPHARM’s premium valuation.
- Pharmaceutical sector benefits from consistent demand but faces regulatory and pricing pressures.
🔎 Conclusion
TORNTPHARM is a good candidate for long-term investment, supported by strong fundamentals, profitability, and moderate debt. However, valuations are stretched compared to industry peers. Entry is ideal near 3,900–4,100 ₹. Existing holders can continue for 3–5 years, with partial exits near 4,450–4,500 ₹ to lock in gains. Long-term prospects remain positive, but valuation risks must be monitored closely.